BioCentury | Aug 4, 2018
Finance

Functions of formulation

...EC had approved HyQvia in May 2013, followed by Herceptin SC in August 2013 and MabThera SC...
...recombinant human hyaluronidase $10 $37 $47 Mid-single digit 09/10/07 Roche (SIX:ROG; OTCQX:RHHBY) 13 Cancer Rituxan Hycela subcutaneous rituximab...
...Silver Spring, Md. Emily Cukier, Senior Writer Hylenex (rHuPH20, Enhanze SC) HyQvia, ig infusion 10% (HyQ) Rituxan Hycela (subcutaneous mabthera, subcutaneous rituximab, MabThera SC) Halozyme...
BioCentury | Jul 27, 2018
Company News

Roche, other pharmas follow suit to halt price increases

...of 3%. These include Avastin bevacizumab, Herceptin trastuzumab, Perjeta pertuzumab, Kadcyla trastuzumab emtansine, Rituxan rituximab, Rituxan Hycela...
BioCentury | Jul 20, 2018
Company News

Roche, other pharmas follow suit to halt price increases

...of 3%. These include Avastin bevacizumab, Herceptin trastuzumab, Perjeta pertuzumab, Kadcyla trastuzumab emtansine, Rituxan rituximab, Rituxan Hycela...
BioCentury | Jul 12, 2018
Regulation

Making patients partners

...Inc. unit to include data from patient preference surveys on the label of its Rituxan Hycela subcutaneous rituximab...
BioCentury | Feb 16, 2018
Clinical News

FDA grants Priority Review to Rituxan for pemphigus vulgaris

...from FDA for the indication (see BioCentury, April 19, 2017 ). Roche markets IV and subcutaneous rituximab...
BioCentury | Dec 23, 2017
Regulation

Prioritizing preferences

...included patient preference information on a drug label with the approval of Genentech Inc.’s Rituxan Hycela subcutaneous rituximab...
BioCentury | Dec 22, 2017
Regulation

Preference pioneers

...Rituxan Hycela subcutaneous rituximab provides the first example of how companies can get patient preference data on...
...which formulation patients preferred, how strongly and why. Over three-quarters of patients in PrefMab preferred Rituxan Hycela...
...study (PrefMab).” Annals of Oncology (2017) Emily Cukier-Meisner, Senior Writer Subcutaneous rituximab Genentech Inc. Roche patient experience data patient preference studies patient-focused drug development PrefMab Rituxan Hycela...
BioCentury | Jul 14, 2017
Clinical News

FDA approves subcutaneous rituximab

...The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA approved Rituxan Hycela subcutaneous rituximab to treat previously...
...NHL, DLBCL, rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. Roche markets IV and subcutaneous rituximab...
...NASDAQ:HALO), San Diego, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Rituxan Hycela subcutaneous rituximab (subcutaneous MabThera) Business: Cancer Alicia Parker Subcutaneous rituximab Biogen...
BioCentury | Apr 19, 2017
Clinical News

Rituxan regulatory update

...antigen also has Orphan Drug designation from FDA for the indication. Roche markets IV and subcutaneous rituximab...
BioCentury | Mar 31, 2017
Clinical News

Subcutaneous rituximab regulatory update

...FDA’s Oncologic Drugs Advisory Committee voted 11-0 that the benefit-risk of subcutaneous rituximab from Roche’s Genentech unit...
...NHL, DLBCL, rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. Roche markets IV and subcutaneous rituximab...
...Inc. (NASDAQ:HALO), San Diego, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Subcutaneous rituximab (subcutaneous MabThera) Business: Cancer Julian Zhu Subcutaneous MabThera Subcutaneous rituximab Biogen...
Items per page:
1 - 10 of 29